Viking Therapeutics Releases Q2 2026 Financial Results

[ad_1] AlphaStreet Newsdesk powered by AlphaStreet Intelligence VKTX|EPS -$1.10 vs -$1.21 est (+9.1%)|Rev $0 vs $0 est|Net Loss $128.0M Viking Therapeutics, Inc. reported a narrower-than-expected quarterly loss, as the clinical-stage biopharmaceutical company continues developing therapies for metabolic and endocrine disorders…